Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)

Day, James H.; Briscoe, Maureen P.; Rafeiro, Elizabeth; Ratz, Jodan D.

doi:10.1111/j.1368-5031.2004.0117.x

Cited by 83 publications

(48 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…56 -59 Recent publications have suggested that, at manufacturer's recommended doses, levocetirizine is less sedating than cetirizine 60 and desloratadine causes negligible somnolence. 49,61 However, it should be pointed out that "mean results" do not reveal everything as some patients may show considerable somnolence whereas others are unaffected.…”

Section: Unwanted Effects Somnolencementioning

confidence: 99%

Pharmacology of Antihistamines

Church

2011

World Allergy Organization Journal

View full text Add to dashboard Cite

This article reviews the molecular biology of the interaction of histamine with its H 1 -receptor and describes the concept that H 1 -antihistamines are not receptor antagonists but are inverse agonists i.e. they produce the opposite effect on the receptor to histamine. It then discourages the use of first-generation H 1 -antihistamines in clinical practice today for two main reasons. First, they are less effective than second generation H 1 -antihistamines. Second, they have unwanted side effects, particularly central nervous system and anti-cholinergic effects, and have the potential for causing severe toxic reactions which are not shared by second-generation H 1 -antihistamines. There are many efficacious and safe second-generation H 1 -antihistamines on the market for the treatment of allergic disease. Of the three drugs highlighted in this review, levocetirizine and fexofenadine are the most efficacious in humans in vivo. However, levocetirizine may cause somnolence in susceptible individuals while fexofenadine has a relatively short duration of action requiring twice daily administration for full all round daily protection. While desloratadine is less efficacious, it has the advantages of rarely causing somnolence and having a long duration of action. Lastly, all H 1 -antihistamines have anti-inflammatory effects but it requires regular daily dosing rather than dosing 'on-demand' for this effect to be clinically demonstrable.

show abstract

Section: Unwanted Effects Somnolencementioning

confidence: 99%

Pharmacology of Antihistamines

Church

2011

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

“…[5] The latest-generation potent antihistamines such as desloratadine and levocetirizine have shown improved quality of life in allergic rhinitis studies. [6,7] Montelukast, a leukotriene receptor antagonist, significantly improves daytime and nighttime symptoms in patients with allergic rhinitis and is now an approved therapy for allergic rhinitis. [8] This study compares desloratadine monotherapy and combination montelukast with desloratadine on quality of life in allergic rhinitis.…”

mentioning

confidence: 99%

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Erdoğan

Şanlı²,

Paksoy³

et al. 2014

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

Objectives: This study aims to compare the effectiveness of desloratadine monotherapy and desloratadine plus montelukast combination therapy on quality of life in patients with persistent allergic rhinitis. Patients and Methods:This study consists of 40 patients (28 females, 12 males, mean age 29.8 years; range 17 to 44 years) referred to ear, nose, and throat outpatient clinic between May 2010 and September 2010. A six-week randomized, doubleblind, cross-sectional study was performed in two arms: In group 1, 20 patients received desloratadine (5 mg/d) alone; in group 2, 20 patients received desloratadine (5 mg) plus montelukast (10 mg) combination therapy. Quality of life was assessed on the day before starting treatment and on the last day of each treatment period using the Rhinoconjunctivitis Quality of Life Questionnaire and Nighttime Symptom Scores. Results:In group 1, the mean quality of life scores before and after treatment were 3.17 and 2.43, respectively. In group 2, the mean quality of life scores before and after treatment were 2.94 and 1.73, respectively. Conclusion:Desloratadine plus montelukast combination therapy may have a positive impact on quality of life, sleep symptoms in particular.Keywords: Desloratadine; montelukast; persistent allergic rhinitis; quality of life.Amaç: Bu çalışmada inatçı alerjik rinit hastalarında desloratadin monoterapisi ve desloratadin artı montelukast kombinasyon tedavisinin yaşam kalitesi üzerine etkinliği karşılaştırıldı. Bulgular: Grup 1'de tedavi öncesi ve sonrası ortalama yaşam kalitesi skoru, sırasıyla 3.17 ve 2.43 idi. Grup 2'de ise, tedavi öncesi ve sonrası ortalama yaşam kalitesi skoru, sırasıyla 2.94 ve 1.73 idi.Sonuç: Desloratadin artı montelukast kombinasyon tedavisinin, özellikle uyku semptomları olmak üzere, yaşam kalitesi üzerine olumlu bir etkisi olabilir.Anahtar Sözcükler: Desloratadin; montelukast; inatçı allerjik rinit; yaşam kalitesi.

show abstract

“…Of these, two studies were conducted in the Vienna Challenge Chamber (VCC) in a cross-over design and compared the efficacy of levocetirizine, loratadine/fexofenadine, and placebo28,29. Two other comparative studies were conducted in an environmental exposure unit (EEU) by Day et al 30,31. and in an environmental exposure chamber (EEC) by Patel and Patel 32 to evaluate the efficacy of levocetirizine with desloratadine or montelukast as a control medicine in studies with a parallel-group design.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of fluticasone furoate nasal spray and levocetirizine in patients with Japanese cedar pollinosis subjected to an artificial exposure chamber

Hashiguchi

Kanzaki

Wakabayashi

et al. 2013

Journal of Drug Assessment

View full text Add to dashboard Cite

ObjectiveThis study investigated the clinical efficacy of a combination therapy of levocetirizine (LCTZ) and fluticasone furoate nasal spray (FFNS), compared with LCTZ monotherapy, for the suppression of seasonal allergic rhinitis (SAR) symptoms induced in an artificial exposure chamber.MethodsThis study was a single-center, placebo-controlled, randomized, 3-way cross-over comparative study performed in 42 Japanese cedar pollinosis patients. These subjects received (1) LCTZ plus FFNS (combination group), (2) LCTZ plus FFNS placebo (monotherapy group), or (3) LCTZ placebo plus FFNS placebo (placebo group) once on the night prior to exposure, with a 1-week washout period between exposures. Nasal (sneezing, rhinorrhea, nasal congestion, and itchy nose) and ocular (eye itching and tearing) symptoms were recorded every 15 min, and the number of sneezes, nose blowing events, and the amount of nasal secretions were measured during exposure. The primary end-point was the cumulative incidence of SAR symptoms during exposure and the ‘ime to occurrence of symptoms’. The secondary end-points were the total nasal symptom score, the ocular symptom score, the amount of nasal discharge, and the number of sneezes and nose blowing events.ResultsAt all the measurement points, the lowest cumulative incidences for the nasal symptoms were observed in the combination group, followed by the monotherapy and placebo groups. All the subjects in the placebo group developed nasal symptoms within 2 h after pollen exposure, while three and eight subjects in the monotherapy and combination groups, respectively, did not develop any nasal symptoms during exposure. In addition, combination therapy delayed the onset of symptoms.ConclusionsThe results demonstrated that combination therapy with FFNS and LCTZ significantly suppressed the induced SAR symptoms and delayed the onset of symptoms compared with LCTZ monotherapy and placebo. Although the conditions of the allergen challenge study using an exposure chamber are different from those in real life, combination therapy with FF and LCTZ was confirmed to be an effective treatment for SAR.

show abstract

Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)

Cited by 83 publications

References 45 publications

Pharmacology of Antihistamines

Pharmacology of Antihistamines

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Efficacy of fluticasone furoate nasal spray and levocetirizine in patients with Japanese cedar pollinosis subjected to an artificial exposure chamber

Contact Info

Product

Resources

About